<DOC>
	<DOCNO>NCT02847429</DOCNO>
	<brief_summary>This multicenter , randomize , double-blinded , placebo-controlled , trial oral crenolanib versus oral placebo combination best supportive care subject advance metastatic GIST D842V mutation PDGFRA gene . Approximately 120 subject randomize 2:1 ratio receive either crenolanib 100 mg match placebo orally ( PO ) 3 time daily ( TID ) combination best supportive care .</brief_summary>
	<brief_title>Randomized Trial Crenolanib Subjects With D842V Mutated GIST</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Crenolanib</mesh_term>
	<criteria>1 . Histologically cytologicallyconfirmed advanced metastatic GIST D842V mutation PDGFRA gene determine central laboratory test 2 . Measurable disease per modify RECIST 1.1 • A lesion area previously treat local therapy ( e.g . radiation , surgery , cryotherapy ) consider measurable disease long objective evidence progression lesion prior randomization 3 . Subjects ( male female ) ≥ 18 year age 4 . Female subject reproductive potential must negative serum urine pregnancy test 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 1 . Severe liver disease ( e.g . cirrhosis , nonalcoholic steatohepatitis , sclerosing cholangitis ) 2 . Known , active infection hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) 3 . Female subject pregnant breastfeeding , plan become pregnant within 30 day end treatment 4 . Systemic anticancer treatment ( e.g . chemotherapy , tyrosine kinase inhibitor , immunotherapy , investigational agent ) investigational device within 3 week 5 halflives ( drug 's halflife subject know ) prior randomization , whichever short</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>